Skip to main content
AAPM&R 2025 Main banner
JFK
Final Program


Official Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
On Demand
On Demand
In-Person
In-Person
Livestream
Livestream
Invite Only
Invite Only
Ticketed
Ticketed
Coffee Break
Coffee Break
Meal
Meal
Reception
Reception
Rate ePoster

Pain and Spine Medicine

Reporting Quality of Clinical Trials on Platelet-Rich Plasma for Low Back Pain: A Systematic Review of Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics Guidelines

Friday, October 24, 2025
8:00 AM - 9:15 AM MT
Location: Kiosk 10
Disclosure(s):
Daniel De La Huerta Meza, MD: No financial relationships to disclose
Antonio Madrazo Ibarra, MD: No financial relationships to disclose
Background and/or Objectives: The Minimum Information for Studies Evaluating Biologics in Orthopedics (MIBO) guidelines, published in 2017, provide a comprehensive list of the minimum information that should be reported by studies using biologics like platelet-rich plasma (PRP). These guidelines aim to enhance research transparency, standardize reporting, facilitate replication, and address outcome variability.

Design: Systematic review of randomized controlled trials evaluating PRP for low back pain.

Setting : Clinical trials evaluating PRP for low back pain published and listed on PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science on or before April 16, 2025.

Participants : Randomized controlled trials of PRP for low back pain, categorized as pre-MIBO (before guideline publication), peri-MIBO (around publication), or post-MIBO (after publication).

Interventions: Not applicable

Main Outcome Measures: Primary outcome was the overall MIBO score (percentage of 23 checklist items reported per study). Secondary outcomes included individual item scores (percentage of studies reporting specific items) and overall item score (average of all individual scores).

Results: 14 studies were analyzed (764 patients): 4 pre-MIBO, 3 peri-MIBO, and 7 post-MIBO. The average MIBO score was 62.88%, with peri-MIBO scoring highest (73.91%) compared to pre-MIBO (50.00%) and post-MIBO (66.46%) (p=0.205). Only 21% of studies achieved >80% compliance. Least reported criteria were whole blood and PRP cell counts (14.29% each), PRP activation (7.14%), and time between preparation steps (14.29%). Significant improvements occurred in reporting whole blood storage and PRP processing in peri-MIBO and post-MIBO groups compared to pre-MIBO.

Conclusions: Despite the publication of the MIBO guidelines in 2017 and a growing number of clinical trials of PRP for low back pain, there has been no significant difference in the overall quality of the data reported in these publications.